HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation.

AbstractBACKGROUND:
Although nifekalant is a class III antiarrhythmic agent without negative inotropic activity, its effect in patients with shock-refractory ventricular fibrillation remains unclear.
METHODS AND RESULTS:
Patients who had an out-of-hospital cardiac arrest with ventricular fibrillation that persisted after 3 shocks from an external defibrillator, intravenous epinephrine, and another shock were retrospectively studied. The patients received lidocaine from January 1997 through June 2001 and nifekalant from July 2001 through December 2004. Short-term survival rates (survival to hospital admission and 24-h survival) were compared between the groups. The study group comprised 120 patients (mean age: 62+/-16 years): 55 received nifekalant and 65 received lidocaine. Age, sex, history of ischemic heart disease, whether arrest was witnessed or not and time to arrival at the hospital did not differ significantly between the groups. As compared with lidocaine, nifekalant was associated with significantly higher rates of survival to hospital admission (67% vs 37%, p<0.001) and 24-h survival (53% vs 31%, p=0.01). Multivariate analysis showed that treatment with nifekalant and early initiation of cardiopulmonary resuscitation were independent predictors of 24-h survival.
CONCLUSIONS:
As compared with lidocaine, nifekalant may improve short-term survival in patients with out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation.
AuthorsYoshio Tahara, Kazuo Kimura, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Kiyoshi Hibi, Hideshi Toyama, Takayuki Kosuge, Yoshihiro Moriwaki, Noriyuki Suzuki, Mitsugi Sugiyama, Satoshi Umemura
JournalCirculation journal : official journal of the Japanese Circulation Society (Circ J) Vol. 70 Issue 4 Pg. 442-6 (Apr 2006) ISSN: 1346-9843 [Print] Japan
PMID16565562 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Pyrimidinones
  • nifekalant
  • Lidocaine
  • Epinephrine
Topics
  • Aged
  • Anti-Arrhythmia Agents (therapeutic use)
  • Cardiopulmonary Resuscitation
  • Epinephrine (therapeutic use)
  • Female
  • Heart Arrest (drug therapy, mortality, physiopathology)
  • Humans
  • Lidocaine (therapeutic use)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pyrimidinones (therapeutic use)
  • Retrospective Studies
  • Survival Rate
  • Time Factors
  • Ventricular Fibrillation (drug therapy, etiology, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: